A New Class of Cell Therapies to Target Solid Tumors

Episode Summary

Executive Summary: The episode explains why the FDA’s first approved TIL therapy marks a turning point for cell therapy in solid tumors. Jason Bach of CTMC contrasts CAR-T’s success in blood cancers with its limits in solid tumors, describes how TILs are harvested from tumors, expanded, and reinfused, and argues that manufacturing, engineering, and lower-cost production could make these therapies more broadly effective and commercially viable.

Main Topics: CAR-T’s breakthrough in blood cancers (Priority: 5/5): Bach describes CAR-T as transformational for hematologic malignancies because it produced durable complete responses in patients with few or no alternatives, establishing the promise of cell therapy. Limitations of CAR-T for solid tumors (Priority: 5/5): The discussion highlights logistical, manufacturing, cost, and biological barriers that have limited CAR-T’s success in solid tumors, including heterogeneity and the tumor microenvironment. FDA approval of the first TIL therapy (Priority: 5/5): The approval of Iovance’s lifileucel for advanced melanoma is framed as a major regulatory milestone that validates TILs and creates a clearer path for industry participation. How TIL therapies work (Priority: 5/5): Bach explains that TILs are taken from a patient’s tumor, expanded and rejuvenated ex vivo, and reinfused after lymphodepleting chemotherapy, leveraging cells already primed to attack the cancer. Manufacturing and scalability challenges (Priority: 4/5): The episode details the difficulty of reproducibly manufacturing autologous cell therapies, especially from exhausted tumor-derived cells and in patients previously treated with checkpoint inhibitors. Future innovation: engineering, armoring, and combinations (Priority: 4/5): Bach argues that second-generation TILs with added engineering, CRISPR edits, or resistance to the tumor microenvironment could improve potency, safety, and applicability across tumors. CTMC’s industrialization model (Priority: 4/5): CTMC positions itself as a bridge between academic innovation and commercial development, offering manufacturing and clinical infrastructure to help biotechs move cell therapies into patients.

Key Arguments: CAR-T proved cell therapy can generate deep, durable responses and even long-term remissions in patients who had exhausted other options. Despite their success, CAR-T therapies are constrained by personalized manufacturing, supply limitations, and high upfront costs. TIL therapies may overcome key CAR-T limitations in solid tumors because they are polyclonal and can target multiple antigens simultaneously. The first FDA approval of a TIL therapy removes a major regulatory uncertainty and should encourage broader industry engagement. TILs have a natural advantage because they are already tumor-homing cells selected by the body; manufacturing mainly amplifies and rejuvenates them. The main safety burden for first-generation TILs appears tied to lymphodepletion and IL-2 rather than the cells themselves. Second-generation TILs that are engineered or armored could better resist the tumor microenvironment and improve efficacy. Manufacturing innovations and automation can lower costs, but the field is still early and will remain expensive until processes mature. Even with high upfront pricing, single-dose curative therapies may be economically favorable over repeated long-term cancer treatments.

Data Points: CAR-T treatment cost: $400,000 to $500,000 - Bach cites typical sticker-shock pricing for CAR-T therapies, while noting the costs may be favorable in context. Emily Whitehead timeline: 12+ years out from CAR-T treatment - Used as an example of durability and long-term remission after pediatric CAR-T. Emily Whitehead age at trial: 7 years old - She was treated on a clinical trial after multiple prior therapies had failed. Pre-CAR-T medical bills: well in excess of $1 million - Her parents reported substantial prior treatment expenses before CAR-T. First FDA-approved TIL therapy timing: February - The FDA approved lifileucel, the first TIL therapy, for advanced melanoma in February. Duration of TIL research: more than 3 decades - TILs have been studied since work beginning at the National Cancer Institute and academic centers. CTMC TIL batches: upwards of more than 100 batches - Bach says CTMC has manufactured a large number of TIL batches over several years. CTMC TIL experience: more than 10 to more than 15 years - CTMC personnel include researchers with long-standing TIL development and manufacturing experience. Lymphodepletion chemotherapy: 5 to 7 days - Patients receive this regimen before TIL infusion to make room for the new cells. Post-infusion monitoring window: first 2 to 3 weeks - Most observed side effects for first-generation TIL therapy occur early after infusion. Response assessment timing: 1 month, 3 months, and 6 months+ - Tumor shrinkage from TILs tends to deepen gradually over months rather than days.

Pivotal Quotes: "CAR-T therapies have been transformational for the treatment of heme malignancies" — Jason Bach: He opens by explaining why cell therapy gained momentum in blood cancers. "It’s a big step forward." — Jason Bach: His characterization of the first FDA approval of a TIL therapy. "these are the cells that are already selected by the body and are already trying to attack the tumor but just need a little bit of help" — Jason Bach: He explains the core biological rationale behind TIL therapy.

Implications: The first TIL approval validates solid-tumor cell therapy and may accelerate investment, engineering, and manufacturing innovation. If potency improves and costs fall, TILs could become a broader, durable alternative to repeated cancer treatments.